Background: Tumor metastasis is responsible for most cancer death worldwide, which lacks curative treatment. Purpose: The objective of this study was to eliminate tumor and control the development of tumor metastasis.
Introduction
Superior strides in antitumor strategies have modestly improved the clinical outcomes, the mortality of tumor still remains high owing to tumor recurrence and metastasis. [1] [2] [3] [4] [5] [6] [7] [8] Immunotherapy has been well concerned due to its function of controlling the development of distant metastatic tumor. [9] [10] [11] In particular, checkpoint inhibitors and chimeric antigen receptor T-cell immunotherapy have been regarded as crucial tools for cancer treatment. [12] [13] [14] [15] [16] [17] [18] [19] [20] Nevertheless, the application of these two strategies is restricted due to serious side effects, high cost, and large individual variations. [21] [22] [23] [24] More relatively low immune response after treatment of checkpoint inhibitors, which is mainly attributed to "cold" immune microenvironment. 4 Hence, exploring novel and powerful methods to achieve the "hot" immune microenvironment and trigger immune response as a prelude for immunotherapy is particularly crucial. Immunogenic cell death (ICD) has been reported to a stimulant circumstance to change "cold" immune microenvironment to "hot" immune microenvironment. [25] [26] [27] Phototherapy as a minimally invasive treatment strategy has been phenomenally applied to tumor ablation. [28] [29] [30] [31] [32] [33] [34] [35] A recent report described that phototherapy induces ICD under laser irradiation. 36 In addition to phototherapy, some other ICD inducers including chemotherapy and ionizing radiation have also been evidenced. 23, 37, 38 However, several intolerable limitations, such as low drug delivery, ignorable cargo release, and single treatment regimen greatly restrict ICD outcome. It is highly expected that the intelligent engineering of a tumor-responsive drug nano-vehicle, the rational combination of phototherapy and chemotherapy is capable of synergistically offering active breakthroughs against limited ICD efficacy. However, there is little work to achieve the desirable high efficiency. In this study, we custom-designed PEG-PCL-IR780-TPZ NPs ( Figure 1 ) as a robust nano-carrier system for higheffectively delivering a phototherapy agent (IR780) and a chemotherapy prodrug (TPZ). The 1 O 2 (one of ROS) generated by IR780 upon an 808-nm laser irradiation released IR780 and TPZ from PEG-PCL-IR780-TPZ NPs after the damage of phospholipid bilayers and achieved a concurrent release. [39] [40] [41] IR780 as a mitochondria-targeting phototherapy agent was able to improve the therapeutic efficacy owing to the phototherapy-sensitivity of mitochondria. 42 , 43 Yang et al reported that TPZ, as a hypoxia-activatable prodrug, had little effect on normal cells but displayed a selectively high toxicity to hypoxic cells. [44] [45] [46] They have also proved that IR780 Damageassociated molecular patterns (DAMPs) including adenosine triphosphate (ATP), high-motility group box 1 (HMGB1), and calreticulin (CRT) were produced as endogenous potentiators and subsequently promoted dendritic cells (DCs) maturation. Eventually, the naïve T-cells were recruited by mature DCs and cytotoxic T lymphocytes (CTLs) including CD8+T, CD4+T, and natural killer (NK) cells were elicited, which played an indispensable in ablating primary tumor and controlling tumor metastasis.
exacerbated tumor hypoxic microenvironment during photodynamic therapy process, which would stimulate TPZ to generate toxic oxidizing radical species (hydroxyl radical and benzotriazinyl radical) through a single-electron reduction reaction. 47 With optimal laser irradiation time, combinational phototherapy and hypoxia-activated chemotherapy elicit ICDmediated adaptive immune response through the tremendous generation of endogenous potentiators, including high-motility group box 1 (HMGB1), adenosine triphosphate (ATP) and calreticulin (CRT). [48] [49] [50] Furtherly, the endogenous potentiators are recognized by dendritic cells (DCs) and contribute to DC maturation. 51 Consequently, the naive T-cells are recruited by mature DCs to activate cytotoxic T lymphocytes (CTLs), including cluster differentiation (CD)8+T, CD4+T, and NK cells, thereafter ablating primary tumor and controlling tumor metastasis. 48, 52, 53 In a word, our study provided three significant findings. First, we disclosed a nano-enabled triggered and controlled nanovehicle. Second, we highlighted that phototherapy of PEG-PCL-IR780-TPZ NPs could exacerbate tumor hypoxia and invoke a hypoxia-activated chemotherapy. Third, we revealed antitumor immune responses stimulated by combinational phototherapy and hypoxia-activated chemotherapy dramatically inhibited tumor metastasis. (IR780 iodide) , 2,2,6,6-tetramethylpiperidine-(TEMP) diethylene glycol, and N,N′-dimethylformamide were purchased from Sigma-Aldrich (Shanghai, China). (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide) MTT assay, 4',6-diamidino-2-phenylindole (DAPI), Calcein-AM/propidium iodide (PI) double staining assay, Dulbecco's modified eagle medium (DMEM), serum-free RPMI-1640 medium, and fetal bovine serum (FBS) were obtained from KeyGen Bio-tech Co., Ltd. (Nanjing, China). Interleukin 12 (IL-12) ELISA kit, fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD11c antibody, anti-calreticulin (CRT) antibody, FITC-conjugated anti-mouse CD4 antibody, P-phycoerythrin (PE)-conjugated anti-mouse CD83 antibody, allophycocyanin (APC)-conjugated anti-mouse CD8 antibody, Peridinin-Chlorophyll-Protein Complex (PerCP)-conjugated anti-mouse CD86 antibody, PE-conjugated anti-mouse CD69 antibody, and Luminescent ATP Detection assay were all brought from Abcam (Shanghai, China). HMGB1 ELISA kit, anti-mouse CD31 antibody, and anti-mouse CD8 antibody were purchased from Bioss (Beijing, China). The secondary antirabbit antibody-Alexa Fluor 488 and other fluorescent antibodies were from Beyotime Institute of Biotechnology (Nanjing, China). All chemical reagents were not further purified again. The mouse-derived breast cancer cell line 4T1 cells were cultured in growth media, which was obtained from the Cell Bank of Shanghai Institutes for Biological Science (Shanghai, China). All specific pathogen free (SPF) mice were purchased from the Comparative Medicine Center of Yangzhou University (Yangzhou, China) and housed under pathogenfree environment. The deionized water was used in the experiment, which was purified from Milli-Q (Millipore, 18.2 MΩ cm
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Preparation of PEG-PCL-IR780-TPZ nanoparticles
The synthesis procedure of poly(ε-caprolactone)-poly (ethylene glycol) (PEG-PCL) was performed as previously described. 54 PEG-PCL-IR780-TPZ nanoparticles (NPs)
were prepared using oil-in-water emulsion solvent diffusion method. 54, 55 Briefly, IR780 (2.5 mg) and TPZ (2.5 mg) were dissolved in 10 mL of dichloromethane and PEG-PCL was dissolved in 10 mL of deionized water. They were mixed and self-assembly under ultrasonication. After ultrasonication for 1 hr, the PEG-PCL-IR 780-TPZ NPs were successfully synthesized and pelleted via centrifugation. Subsequently, the samples were washed thrice with deionized water and stored at 4°C.
Characterization of PEG-PCL-IR780-TPZ NPs
The morphology and size of PEG-PCL NPs and PEG-PCL -IR780-TPZ NPs were directly captured using transmission electron microscope (TEM, JEOL-200CX, Tokyo, Japan). The hydrodynamic diameter of each type of particles was measured by Zetasizer Nano-ZS90 (DLS, UK). UV-vis absorption spectra were determined using the UV-3600 spectrophotometer (Shimadzu, Tokyo, Japan) to ensure the successful encapsulation of hydrophilic small molecular in PEG-PCL NPs. The drug loading and encapsulation efficiency for both IR780 and TPZ were respectively calculated through the standard curves of IR780 and TPZ determined by UV-vis spectrophotometer. The calculation equations of drug loading and encapsulation are as follows: 
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In vitro infrared (IR) imaging
The in vitro photothermal properties of PEG-PCL-IR780-TPZ NPs were assessed using a thermal imaging camera (Fotric 226, Shanghai, China) under the irradiation of an 808 nm laser with a diminishing density (1. ). After that, the PEG-PCL -IR780-TPZ NPs solution with different IR780 concentrations (0, 50 μg/mL and 200 μg/mL) in a 6-well plate was further irradiated under the laser power density at 1.0 W/ cm 2 for 10 min.
In vitro ROS/hypoxia detection
The ROS/hypoxia effect was evaluated using a ROS-ID ® Hypoxia/Oxidative Stress Detection Kit (ENZO, Nanjing, China). First, 4T1 cells were harvested and seeded in a 6-well plate containing DMEM supplemented with 10% FBS for 12 hrs. IR780 (200 μg/mL, according to IR780), PEG-PCL-IR780 (200 μg/mL, according to IR780) and PEG-PCL-IR780-TPZ (200 μg/mL, according to IR780) were added after incubation. Subsequently, cells were exposed to the irradiation of an 808 nm laser (1 W/ cm 2 ) for 5 mins. The hypoxia detection solution was then added into the 6-well plate for another 20 mins in dark.
Finally, cells were washed for three times with PBS, and an IX73 fluorescence microscope (Olympus, Japan) was used to capture the images.
MTT assay
In vitro cell cytotoxicity of PEG-PCL-IR780-TPZ NPs was evaluated using the MTT assay. 
Calcein-AM/PI double staining assay
The calcein-AM/PI double staining was employed to evaluate the cell viability. Briefly, 4T1 cells were seeded into a 6-well plate for 12 hrs under 37°C with 5% CO 2 . Cells were incubated with different concentrations of PEG-PCL-IR780 NPs and PEG-PCL-IR780-TPZ NPs for 12 hrs and exposed to an 808 nm laser irradiation (1.0 W/cm 2 ) for 5 mins or not. The calcein-AM/PI co-staining was performed, and the fluorescence images of live cells, and dead cells were captured using a confocal laser scanning microscope (CLSM, Olympus, FV1000, Tokyo, Japan). The data were analyzed by ImageJ.
Analysis of in vitro ICD biomarkers
To evaluate the in vitro level of immunogenic cell death (ICD) biomarkers, 4T1 cells were co-cultured with IR780 (200 μg/mL, according to IR780), PEG-PCL-IR780 NPs (200 μg/mL, according to IR780) and PEG-PCL-IR780-TPZ NPs (200 μg/mL, according to IR780). After incubation for 12 hrs, an 808 nm laser irradiation was performed for 5 min (the power density of the laser is 1 W/cm 2 ) or not. After another 3 hrs, the supernatant was collected for detecting the release of HMGB1 and/or ATP by ELISA and a chemiluminescence determination kit (Luminescent ATP Detection Assay (Abcam)). Next, 4T1 cells were washed twice with PBS and fixed with paraformaldehyde (4%) for 15 mins. After PBS washing, Bull Serum Albumin (BSA, 6% w/v, incubation: 60 min) was used to block non-specific binding for the antibody. 4T1 cells were then incubated with the primary antibody (anti-CRT antibody, dilution 1:100) overnight at 4°C. Afterward, cells were washed three times with PBS and incubated with Alexa Fluor 488-conjugated secondary antibody (dilution 1:100) in dark at room temperature for 60 mins. Finally, cells were washed and stained with DAPI solution. The fluorescence images were captured using CLSM.
Evaluation of DC maturation
To investigate the DCs maturation, bone marrow-derived DCs (BMDCs) were harvested from mice bone marrow according to the reported method. 59 First, the healthy BALB/c mouse (5 weeks old) was sacrificed, and bone marrow cells were collected under specific pathogen-free condition. Red blood cell lysis solution was added to purify BMDCs. After that, cells were cultured in serum-free RPMI-1640 medium supplemented with 10% interleukin-4 (IL-4, 10 ng/mL) and granulocyte-macrophage colony-stimulating factor (GM-CSF, 10 ng/mL) at 37°C with 5% CO 2 . After incubation for seven days, the purified BMDCs were obtained. Meanwhile, cells were incubated with IR780 (200 μg/mL, according to IR780), PEG-PCL-IR780 NPs (200 μg/ mL, according to IR780) and PEG-PCL-IR780-TPZ NPs (200 μg/mL, according to IR780). An 808 nm laser irradiation (1 W/cm 2 , 5 mins) for 24 hrs was employed to trigger the DC maturation. Cells were stained with FITC-conjugated anti-mouse CD11c antibody, PE-conjugated anti-mouse CD83 antibody, PerCP-conjugated anti-mouse CD86 antibody, and then assessed using flow cytometry. Meanwhile, the level of IL-12 effector in the supernatant was estimated using IL-12 ELISA kits as a protocol of reagent.
The xenograft mice tumor models
The healthy female BALB/c mice (5 weeks old) were purchased from Comparative Medicine Centre of Yangzhou University housed under specific pathogen-free environment. Animal experiments were approved by the Care Committee of Nanjing University (including guidelines for animal care & use, and guidelines for euthanasia of mice, Protocol #: 20180212-013). A total of 5×10 6 4T1 cells per mice were subcutaneously injected. Tumor volume was monitored every three days using a vernier caliper. Three days after mice inoculated with 4T1 cells on the right armpit, the second batch of 4T1 cells ( 5×10 6 ) was intravenously injected through tail to establish the artificial mimic metastatic model.
In vivo IR imaging
The photothermal effect was evaluated using infrared (IR) thermal camera to ensure the in vivo effective therapy. Briefly, 4T1-tumor-bearing mice were intravenously injected with PBS or PEG-PCL-IR780-TPZ NPs (1.5 mg/kg, according to IR780). Twelve hours later, 4T1-tumor-bearing mice were irradiated by an 808 nm laser for 10 mins at the power density of 1 W/cm 2 . All thermographs were analyzed using the Fotric AnalyzIR software.
In vivo antitumor efficacy
For assessing the therapy efficacy of PEG-PCL-IR780-TPZ NPs, 4T1-tumor-bearing mice were randomly divided into four groups, including PBS, IR780 (1.5 mg/kg, according to IR780), PEG-PCL-IR780 (1.5 mg/kg, according to IR780) and PEG-PCL-IR780-TPZ (1.5 mg/kg, according to IR780). Mice in the PBS group were administrated with 100 μL of PBS as negative controls. Mice in the other groups were treated with 100 μL of nanoparticles via intravenous injection, followed by an 808 nm laser irradiation (1 W/cm 2 ) for 5 mins. The average tumor volume was recorded. Relative tumor volume (RTV) was calculated as follows: RTV=V/V 0 , in which V was indicative of the volume recorded every three days and V 0 was indicative of primitive volume. After the final treatment, the mice were humanely sacrificed for harvesting major organs that were subjected to further histopathology analysis.
Histopathology analysis
Organs and tumor tissues were harvested, washed three times with PBS, and immediately fixed in paraformaldehyde solution (4% w/v) for one day. Afterward, the tissues were embedded and sectioned to 30 μm slices. Finally, the slices were stained using immunohistochemistry (IHC) staining (Ki67 and HIF), immunofluorescence staining (CD31), and hematoxylin and eosin (H&E).
In vivo micro-positron emission tomography (PET) imaging
The evaluation of tumor hypoxia was carried out using micro-PET imaging. Mice in each treatment group (PBS, IR780+ laser, PEG-PCL-IR780+ laser, and PEG-PCL-IR 780-TPZ + laser) received an intravenous injection of 18 F-fluoromisonidazole ( 18 F-FMISO, 75 μCi/mouse, 100 μL). Afterward, the tumor hypoxia in mice was photographed using the Inveon small animal PET/CT system (Siemens, PA). All images were reconstructed with Inveon Software (Siemens, PA).
Lung metastasis evaluation
The lung metastasis inhibition was investigated using the artificial mimic lung metastatic model established as above-described. Specifically, 22 days after therapy, the lung metastatic mice were humanely sacrificed. The lungs were collected and washed. Lung metastases were indicated by the visible white nodules in the excised lungs. The number of lung metastatic nodules was carefully counted through an Olympus microscope. H&E staining of the excised lungs soaked in solution (4% w/v paraformaldehyde) was also employed to assess the histology and pathology.
Evaluation of in vivo antitumor immunity
To assess the in vivo antitumor immunity, the sections of tumor tissue were stained using immunofluorescence for CRT. The infiltration of CD8+ T cells in the tumor was investigated using immunohistochemistry (IHC). Briefly, tumor tissues were harvested and further digested into discrete single cells. Subsequently, the discrete cells were aspirated from suspensions and labeled using PerCPconjugated anti-mouse CD86 antibody, and FITCconjugated anti-mouse CD11c antibody to identify the mature DCs. APC-conjugated anti-mouse CD8 antibody, FITC-conjugated anti-mouse CD4 antibody, and PEconjugated anti-mouse CD69 antibody were used to identify the CD8+ cells and CD4+ T cells, respectively. Finally, the flow cytometry was utilized to identify the activated effector cells.
In vivo biochemical assay
Mouse blood and tissue were collected into a sodium Ethylene Diamine Tetraacetic Acid (EDTA) anticoagulant tube to assess the cytotoxicity of PEG-PCL-IR780-TPZ NPs in vivo. The biochemical analysis was conducted to detect the system side-effect in vivo, including levels of red blood cell (RBC), white blood cell (WBC), hemoglobin concentration (HGB), mean corpuscular hemoglobin content (MCH), and mean corpuscular hemoglobin concentration (MCHC). The level of platelets (PLT) was an important index for evaluating the spleen function.
Statistical analysis
All statistical analyses were carried out using one-way ANOVA. All data were shown as means±standard deviation. *P-value <0.05 represented the significant differences.
Results and discussion
Characterization of the PEG-PCL-IR780-TPZ NPs
The morphology of PEG-PCL NPs and PEG-PCL-IR 780-TPZ NPs is shown in Figure 2A and B. The average size of PEG-PCL NPs was very close to that of PEG-PCL-IR780-TPZ NPs. As exhibited in Figure 2C , the mean hydrodynamic diameter of PEG-PCL-IR780-TPZ NPs was about 135 nm, which was little larger than that of PEG-PCL NPs (125 nm). The absorption spectra showed that PEG-PCL had no remarkable peaks in NIR window ( Figure 2D ). However, the UV-vis spectra of PEG-PCL-IR780-TPZ NPs had two peaks, which attributed to TPZ and IR780, evidencing the successful encapsulation of TPZ and IR780 in PEG-PCL NPs. Figures S1 and S2 exhibited the absorption curves of IR780 and TPZ with different concentrations, respectively. Based on the earlier data, the standard absorbance versus concentration curves of IR780 and TPZ was quantified (Figures S3 and S4) . The drug loading and encapsulation efficiency for IR780 (3.28%, 70.23%) and TPZ (3.33%, 71.28%) in PEG-PCL-IR780-TPZ NPs were calculated. Considering the stability of drug delivery system (DDS) is a precondition for in vivo application, serum or PBS was mixed with PEG-PCL-IR780-TPZ NPs at 37°C to mimic the in vivo physiological condition. As depicted in Figure 2E , no obvious changes in size were noticed during a period of 8 days, illustrating the outstanding stability of PEG-PCL-IR780-TPZ NPs as a DDS. The drug release was an important role for intelligent DDS. It was reported that excessive ROS impair PEG-PCL, thus leading to the subsequent cargo release. IR780 as NIR photosensitizers are capable of generating singlet oxygen (one type of ROS). We speculated whether PEG-PCL-IR780-TPZ NPs could rapidly release IR780 once exposed to the irradiation of an 808 nm laser. As depicted in Figure 2F and Figure S5 , no remark release of IR780 and TPZ from PEG-PCL-IR 780-TPZ NPs was detected without the laser irradiation, suggesting that PEG-PCL-IR780-TPZ NPs were considerably stable in circulation. In contrast, with the irradiation of an 808 nm laser, PEG-PCL-IR780-TPZ NPs were rapidly disintegrated, thus robustly and effectively unleashing IR780 and TPZ.
In vitro photothermal and photodynamic property of PEG-PCL-IR780-TPZ NPs
In vitro photothermal property of PEG-PCL-IR780-TPZ NPs was assessed using an IR camera. A powerdependent, concentration-dependent, and timedependent photothermal transformation curves were, respectively, displayed in Figure 3A -C. From these data, PEG-PCL-IR780-TPZ NPs were highlighted to be a potential agent for photothermal therapy. In vitro photodynamic property of PEG-PCL-IR780-TPZ NPs was investigated by assessing ROS level using a ROS/hypoxia ELISA Kit. The kit includes fluorogenic probes for hypoxia (red) and ROS (green). Red hypoxia detection probe is a non-fluorescent or weakly fluorescent aromatic compound containing a nitro (NO 2 ) moiety. Due to a nitroreductase activity present in hypoxic cells, the nitro group is converted in a series of chemical steps to hydroxylamine (NHOH) and amino (NH 2 ) group, the original molecule then degrades releasing the fluorescent probe. The ROS reagent is a non-fluorescent, cell-permeable total ROS detection dye which reacts directly with a wide range of reactive species, such as hydrogen peroxide, peroxynitrite, and hydroxyl radicals, yielding a green fluorescent product indicative of cellular production of different ROS/RNS types. As indicated in Figure 3D , no visual fluorescence was observed in the control group, suggesting neither ROS nor hypoxia in 4T1 cells. After co-culture of 4T1 cells with IR780, PEG-PCL-IR780 NPs, and PEG-PCL-IR780-TPZ NPs and irradiated by an 808 nm laser (1 W/cm 2 ), both green and red fluorescence were revealed, which represented the emergences of ROS and hypoxia. Additionally, we also employed TEMP spin-trapping EPR technology for the singlet oxygen detection. As indicated in Figure S6 , characteristic peaks ascribed to singlet oxygen were both observed in IR780 and PEG-PCL-IR 780-TPZ NPs, illustrating the generation of ROS and demonstrating the feasibility of PEG-PCL-IR780-TPZ NPs for PDT treatment. Based on the decomposition rate of Na 2 -ADPA by PEG-PCL-IR780-TPZ NPs and ICG as well as the absorbance intensity change of Na 2 -ADPA at 378 nm ( Figures S7 and S8 
In vitro antitumor efficacy
Bearing negligible system toxicity is a precondition for in vivo application, thus we assessed the cell viability in IR780, PEG-PCL-IR780 NPs, and PEG-PCL-IR780-TPZ NPs groups without laser irradiation. From Figure 4A , no significant cell toxicity was identified in all groups without the addition of laser irradiation. The cell viability of all groups was above 90%, even at the highest concentration (TPZ, 2.3 μg/mL, IR780, 2.2 μg/mL). On the contrary, the engagement of an 808 nm laser (5 mins, 1 W/cm 2 ) would be game changing and IR780, PEG-PCL-IR780 NPs, and PEG-PCL-IR780-TPZ NPs groups all compromised cell viability ( Figure 4B ). In PEG-PCL-IR780 group, when the IR780 concentration increased up to 2.2 μg/mL, the cell viability declined to 56.8%±7.2%. Particularly, the additional engagement of TPZ in PEG-PCL-IR780-TPZ NPs group exhibited better antitumor outcome. When PEG-PCL-IR780-TPZ NPs increased to the highest concentration (TPZ, 2.3 μg/mL, IR780, 2.2 μg/mL), cell viability was 32.7%±9.6%. As a prodrug, TPZ has no system toxicity in normal condition while hypoxic microenvironment could active TPZ and produce the toxic oxidizing radicals. 54, 60 We have demonstrated the capacity of PEG-PCL-IR780-TPZ NPs to cause a serious hypoxic microenvironment. Therefore, the combinational encapsulation of IR780 and TPZ provided favorable potential for hypoxia-activated chemotherapy. Meanwhile, PEG-PCL-IR780-TPZ NPs achieved a synergistic effect of phototherapy and hypoxia-activated chemotherapy. Calcein-AM/PI co-staining was performed to further assess the in vitro therapy outcome. The red fluorescence represented dead cells while the green fluorescence indicated live cells. As illustrated in Figure 4C , no obvious red fluorescence was detected in each group without the help of laser irradiation. Nonetheless, each group reflected red fluorescence to different extents when they were irradiated by laser. In particular, PEG-PCL-IR780-TPZ NPs showed the maximum cell death, indicating its excellent synergistic antitumor effect.
In vitro evaluation of induced ICD
Very recently, ICD has drawn exploding attention owing to its robust immune response and outstanding outcome in tumor therapeutic. Hence, ICD in different groups was assessed through the examination of ICD markers (CRT, ATP, and HMGB1). As displayed in Figure 5A , PEG-PCL-IR780-TPZ NPs without the irradiation exhibited weaker effects on inducing CRT expression. However, after the irradiation, PEG-PCL-IR780-TPZ NPs group revealed visually higher CRT expression than that of other groups. Similarly, in comparison with other groups, PEG-PCL-IR 780-TPZ NPs triggered higher expression in ATP or HMGB1 release ( Figure 5B and C) when exposed to laser. Altogether, we identified that PEG-PCL-IR780-TPZ NPs could invoke ICD during the process of synergic phototherapy and hypoxia-activated chemotherapy.
Since we have already verified the generation of ICD markers (CRT, ATP, and HMGB1) in PEG-PCL-IR780-TPZ NPs + laser group, DCs maturation stimulated by these ICD markers were subsequently evaluated using flow cytometry. As depicted in Figure 5D , expression levels of CD83 and CD86 on cell surface under the treatment of PEG-PCL-IR780-TPZ NPs + laser were remarkably elevated compared with IR780+ laser group and PEG-PCL-IR780 NPs + laser group, implying much pronounced DCs maturation. Furthermore, the expression of IL-12 as a signal cytokine for DCs maturation was tested. As indicated in Figure 5E , PEG-PCL-IR780-TPZ NPs + laser significantly improved the level of IL-12 compared with that of other groups. All these results illustrated that the synergic therapy rendered by PEG-PCL-IR 780-TPZ NPs + laser could fully induce ICD and DCs maturation.
In vivo IR imaging of PEG-PCL-IR780-TPZ NPs
Encouraged by in vitro photothermal conversion efficiency, the PTT properties of PEG-PCL-IR780-TPZ NPs on 4T1-tumorbearing mice were further evaluated. Briefly, 4T1-tumorbearing mice were intravenously injected with PBS (100 μL) or PEG-PCL-IR780-TPZ NPs (100 μL, 1.5 mg/kg, according to IR780). According to the results in Figure 6A and B, mice in control group exhibited a negligible temperature elevation after exposing to an 808 nm laser irradiation for 10 min. However, the temperature of local tumor position reached to 46°C at 2 mins after injection with PEG-PCL-IR780-TPZ NPs and irradiation with an 808 nm laser. Noteworthy, tumor temperature increased up to 54°C within 10 mins, providing an optimal temperature for tumor ablation and ICD production. 36 
In vivo antitumor effect
Considering the excellent in vitro antitumor properties of PEG-PCL-IR780-TPZ NPs, the therapy efficacy of tumor was further investigated. Briefly, 4T1-tumor-bearing mice were randomly divided into four groups, including PBS (100 μL), IR780 (100 μL, 1.5 mg/kg, according to IR780), PEG-PCL-IR780 (100 μL, 1.5 mg/kg, according to IR780), PEG-PCL-IR780-TPZ (100 μL, 1.5 mg/kg, according to IR780). As depicted in Figure 7A , PEG-PCL-IR780-TPZ NPs displayed the greatest tumor inhibition among all treated groups. As displayed in Figure 7B , mouse body weight had no apparent changes after different treatments relative to other groups, suggesting no acute toxicity of PEG-PCL-IR 780-TPZ NPs. Figure 7C and D showed the representative images of 4T1-tumor-bearing mice and separated primary tumor tissues, respectively. These data suggested the best therapeutic outcome in PEG-PCL-IR780-TPZ NPs group. From the H&E staining images ( Figure 7E ) and Ki67 staining images (Figure 7F ), the largest areas of necrosis and the least proliferation rate in PEG-PCL-IR780-TPZ NPs group were illustrated. Accordingly, we concluded that the synergic phototherapy and hypoxia-activated chemotherapy had a wonderful antitumor efficacy.
In vivo hypoxia detection
In light of above results, PEG-PCL-IR780-TPZ NPs exhibited a superior therapeutic outcome for primary tumor ablation compared with PEG-PCL-IR780 NPs. We deduced that the surprising phenomenon was attributed to the hypoxia-activated chemotherapy rendered by TPZ, which could produce the toxic oxidizing radicals under relative tumor hypoxic microenvironment. To evidence the abovementioned hypothesis, in vivo PET imaging, immunohistochemically staining (hypoxiainducible factor (HIF)-1α), and immunofluorescence staining (CD31) were carried out to evaluate the tumor hypoxia, respectively. As depicted in Figure 8A , PEG-PCL-IR780 NPs and PEG-PCL-IR780-TPZ NPs caused more significant oxygen depletion than control group and IR780 treatment group.
Similarity, compared with control and IR780 group, more serious hypoxia degree reflected by (HIF)-1α staining was detected in PEG-PCL-IR780 NPs and PEG-PCL-IR780-TPZ NPs groups ( Figure 8B ), which were attributed to the effective tumor enrichment and oxygen consumption of IR780. Moreover, tumor angiogenesis that supplied the adequate oxygen to tumor was further monitored through CD31 staining. Obviously, tumor blood vessels were damaged severely in PEG-PCL-IR780 NPs and PEG-PCL-IR780-TPZ NPs groups compared with control and IR780 group, which were responsible for serious hypoxia level in tumor ( Figure 8C ). Collectively, all the abovementioned evidences supported that the PEG-PCL-IR780-TPZ NPs could aggravate tumor hypoxia with the help of the irradiation of an 808 nm laser, which subsequently activated the prodrug TPZ and finally featured synergic phototherapy and hypoxia-activated chemotherapy.
Evaluation of PEG-PCL-IR780-TPZ NPs against metastasis in vivo
Fatal metastasis remains a huge challenge for traditional therapy strategies, which is the major reason for cancer deaths. Enlightened by the surprising therapeutic efficacy in vitro and in vivo, we further investigated the effects of nanoparticle-based synergic treatment on triggering the abscopal effect against metastasis. As shown in Figure 9A , the size and number of tumor nodules in mouse lungs of control group were the greatest than that of other groups and PEG-PCL-IR780-TPZ NPs + laser treatment led to a dramatical decrease in the number of metastatic nodules compared to IR780+ laser and PEG-PCL-IR780 NPs + laser treatments. PEG-PCL-IR780-TPZ NPs + laser treatment had the maximum ability to alleviate tumor metastasis than other treatments ( Figure 9B ). Collectively, we demonstrated that synergic phototherapy and hypoxia-activated chemotherapy rendered by PEG-PCL-IR780-TPZ NPs + laser could ablate the primary tumor and control the tumor metastasis.
ICD-mediated antitumor immunity in vivo
We hypothesized that the visual inhibition of tumor metastasis in PEG-PCL-IR780-TPZ NPs + laser group could be explained by the fact that synergic phototherapy and hypoxia-activated chemotherapy would induce antitumor immune responses through the generation of ICD. As indicated in Figure 9C , CRT level on tumor cell surfaces induced by PEG-PCL-IR780-TPZ NPs under an 808 nm laser irradiation was higher than that of IR780 and PEG-PCL-IR780 NPs, which mainly attributed to synergic phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses. After that, the biomarkers (CD11c+CD86+) as the signal for mature DCs were evaluated using FCM and exhibited in Figure S10 . The data showed higher levels of biomarkers on DC cell surface in the PEG-PCL-IR780-TPZ NPs group. Meanwhile, the activated-T lymphocytes infiltrated into tumor tissues was investigated and depicted in Figure 9D and Figure S11 . According to immunohistochemistry ( Figure 9D ), brown signals indicated infiltration of activated CD8+ T cells into tumors, and it was the most pronounced in PEG-PCL-IR780-TPZ NPs group. The effector cells including CD8+ and CD4+ T cells were further assessed by staining with antibodies and conducted using FCM ( Figure S6) . Similarly, more effector cells were witnessed in PEG-PCL-IR780-TPZ NPs group. Taken together, all the results implied that PEG-PCL-IR 780-TPZ NPs armed by an 808 nm laser irradiation could induce the robust anti-tumor immunity for suppressing tumor metastases.
Safety evaluation in vivo
The primary safety evaluation was performed after mice were humanely sacrificed. As described in Figure 10A , the weight ratio of major organs to body weight in PEG-PCL-IR 780-TPZ NPs group was similar to that of control group. Moreover, indexes of aerobic capacity and hematopoietic (HGB, RBC, WBC, etc.) had no obvious changes as displayed in Figure 10B . As indicated in Figure 10C , no visible damage was observed in the major tissues. Taken together, ignorable changes or damages were observed in synergic phototherapy and hypoxia-activated chemotherapy rendered by PEG-PCL-IR780-TPZ NPs, suggesting the potential value of PEG-PCL-IR780-TPZ NPs on clinical application.
Conclusion
In summary, we tailor-made PEG-PCL-IR780-TPZ NPs as a versatile nano-platform for cancer treatment. The platform achieved a smart drug delivery, controlled cargo release, and a robust ICD outcome. Especially, the combination of phototherapy and hypoxia-activated chemotherapy could produce damage-associated molecular patterns (DAMPs) including ATP, HMGB1, and CRT as activated endogenous potentiators, subsequently induce DCs maturation and activation of toxic T lymphocytes. As expected, our platform successfully eliminates the primary tumor and controls the development of tumor metastasis, lighting up the clinical application of cancer treatment.
